Completed PHASE3 INTERVENTIONAL 1-arm NCT01189461

Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

An Open Label, One Year, Non-Comparative Study To Evaluate The Safety And Tolerability Of Intravitreous Pegaptanib Sodium In Patients With Diabetic Macular Edema

Sponsor: Pfizer

Conditions Anti- VGF Inhibitor Diabetic Macular Edema Diabetic Retinopathy

Interventions pegaptanib sodium

Updated 6 times since 2017 Last updated: Jun 27, 2013 Started: Jan 31, 2011 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Anti- VGF Inhibitor and Diabetic Macular Edema and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ferrol, Spain , Frimley, United Kingdom , Girona, Spain , Kuopio, Finland , Lahti, Finland , London, United Kingdom , Madrid, Spain , Reus, Spain , Santiago de Compostela, Spain , Stockholm, Sweden and 1 more location